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Key Points
• The deletion of pfn1 led to
bone marrow failure, loss
of quiescence, increased
apoptosis and mobilization,
and a metabolic switch of
HSCs.
• Pfn1 partially acts through the
axis of pfn1/Ga13/EGR1 to
regulate stem cell retention
and metabolism in the bone
marrow.
How stem cells interact with the microenvironment to regulate their cell fates and
metabolismis largelyunknown.Herewedemonstrated that thedeletionof thecytoskeleton-
modulating protein profilin 1 (pfn1) in hematopoietic stem cell (HSCs) led to bone marrow
failure, loss of quiescence, and mobilization and apoptosis of HSCs in vivo. A switch from
glycolysis tomitochondrial respiration with increased reactive oxygen species (ROS) level
was also observed in HSCs on pfn1 deletion. Importantly, treatment of pfn1-deficient mice
with the antioxidant N-acetyl-L-cysteine reversed the ROS level and loss of quiescence of
HSCs, suggesting that themetabolismismechanistically linkedto thecell cyclequiescence
of stem cells. The actin-binding and proline-binding activities of pfn1 are required for its
function in HSCs. Our study provided evidence that pfn1 at least partially acts through the
axisof pfn1/Ga13/EGR1 to regulate stemcell retentionandmetabolism in thebonemarrow.
(Blood. 2014;123(7):992-1001)
Introduction
In the bone marrow (BM) microenvironment, the fates of hema-
topoietic stem cells (HSCs) are balanced among quiescence, self-
renewal, differentiation, apoptosis, and motility. This balance is
achieved through the dynamic interaction of factors including
transcription factors, epigenetic regulators, cytoskeleton molecules,
and extrinsic cues from the environment. Recently, we demonstrated
that HSCs possess a distinct metabolic proﬁle with a preference for
glycolysis rather than mitochondrial respiration.1 However, the
relationship among cell fates, metabolism, and the microenviron-
ment of HSCs is not well understood.
Proﬁlin 1 (Pfn1) is a ubiquitously expressedmember of the proﬁlin
family. Pfn1 enhances ADP-to-ATP exchange on G-actin and is
capable of adding ATP-bound G-actin to the barbed ends of growing
ﬁlaments. Pfn1 was therefore thought to play a central role in the
regulation of de novo actin polymerization.2 Pfn1 also binds to phos-
phoinositides, phosphatidylinositol-3,4,5-triphosphate, and a number
of proline-rich proteins ranging from those participating in cytoskel-
etal organization to transcriptional control in cells. Binding of pro-
ﬁlins to signaling molecules, such as Arp2/3 complex, Mena, VASP,
N-WASP, dynamin I, and others, further implicates them as regulators
of diverse activities including proliferation, migration, endocytosis,
mRNA splicing, and transcription.3
The pfn1 gene was ﬁrst identiﬁed as a survival essential gene in
Drosophila.4 Homozygous pfn1 knockout mouse embryos die as early
as the 2-cell stage, indicating its essential role in survival and cell
division of embryonic development.2 The roles of pfn1 in motility are
not consistent among different cell types. A number of studies
indicated that pfn1 stimulates migration of endothelial cells, chon-
drocytes, humanmesenchymal stem cells, and granule neurons.3,5-7 By
contrast, pfn1 decreases motility and invasiveness of breast cancer
cells in a mouse model8 and is down-regulated in invasive bladder
cancer cells compared with noninvasive counterparts.9
The in vivo role of pfn1 in tissue-speciﬁc stem cells has not been
reported. The availability of the pfn1ﬂox/ﬂox mice provided us an
opportunity to clarify the function of pfn1 in different tissues and
stem cells in the whole animal. We bred HSC-speciﬁc Cre-ER mice
that express inducible Cre in HSCs10 and pfn1ﬂox/ﬂox mice to in-
ducibly delete pfn1 in HSCs.We used thismodel to study the roles of
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pfn1 in hematopoietic development and to investigate the relation-
ships ofBMenvironment andmetabolism and cell fates ofHSCs.We
showed that, different from its roles in many other types of cells,3,5-7
pfn1 is essential for the retention and quiescence of HSCs in the BM.
Pfn1 also maintains glycolysis to directly control HSC quiescence,
indicating that the unique metabolic property of HSCs is a de-
terminant of quiescence of these stem cells.
Methods
Mice
C57 BL/6 CD45.2 and CD45.1 mice were purchased from the National
Cancer Institute and from the University of Texas Southwestern Medical
Center animal breeding core facility. To obtain an HSC-speciﬁc deletion of
pfn1, C57BL/6 mice carrying the loxP-ﬂanked pfn1 gene3 were crossed with
transgenic C57BL/6 mice expressing the tamoxifen-inducible Cre recombi-
nase under the control of stem cell leukemia (Scl) HSC enhancer10 to produce
Sclpfn1 mice (supplemental Table 1, available on the Blood Web site). For
induction of Cre-ER recombinase, mice received intraperitoneal tamoxifen
(1 mg/0.1 mL of corn oil; Sigma-Aldrich) injections as previously de-
scribed.10 Mice were maintained at the University of Texas Southwestern
Medical Center animal facility. All animal experiments were performedwith
the approval of University of Texas Southwestern Committee on Animal Care.
Flow cytometry, mouse HSC culture, competitive reconstitution
analysis, and homing assay
The isolation of Lin2Sca-11Kit1Flk22CD342 cells (long-term HSCs [LT-
HSCs]), analysis of repopulation of mouse HSCs, and the Hoechst 33342/
pyronin Y staining and bromodeoxyuridine (BrdU) incorporation were per-
formed as previously described.11 Indicated numbers of BM Lin2Sca-11
Kit1Flk22CD342 cells were cultured in serum-free medium supplemented
with stem cell factor, thrombopoietin, and ﬁbroblast growth factor-1 as
previously described.12 The competitive reconstitution analysis was conducted
as we described previously.13,14 Homing assays were performed as described
previously.11,13 Details are included in the supplemental Methods.
Measurement of 13C lactate production, ATP assay, and oxygen
consumption analysis
The metabolic assays were performed essentially as we described.1,15 Details
are described in the supplemental Methods.
Measurement of reactive oxygen species
The measure of reactive oxygen species (ROS) was performed essentially
as described previously.15 Brieﬂy, control and Sclpfn1 Lin2 cells were
incubated with 1 mM 5-(and-6)-carboxy-29,79-Dichloroﬂuorescein diacetate
(carboxy-DCFDA, C-369; Invitrogen) for 30 minutes at 37°C in the dark.
Then, cells were stained for HSCs markers Sca-1-phycoerythrin (PE)/Cy5.5,
C-Kit-Allophycocyanin, CD34-PE, and Flk2-PE and assayed by ﬂow cytometer.
Antibodies were all purchased from BD Biosciences.
Treatment with N-acetyl-L-cysteine
Control and Sclpfn1mice were treated with tamoxifen for 7 days followed by
treatmentwithN-acetyl-L-cysteine (NAC; Sigma-Aldrich) at a dose of 100mg/kg
body weight for another 8 days. NAC was injected into mice intraperitoneally.
Retrovirus infection and quantitative RT-PCR
The retrovirus infection and real-time reverse transcriptase-polymerase chain
reaction (RT-PCR)were performed essentially as previously described,11 and
details are included in the supplementalMethods. Real-timeRT-PCRprimers
are described in supplemental Table 2.
Colony assays
The colony-forming unit (CFU)-erythroid, mature burst-forming unit-erythroid,
CFU-granulocyte macrophage, CFU-pre-B lymphoid progenitor assays were
performed as described previously.13 Details are described in the supplemental
Methods.
Transwell experiments
A total of 20 000 ﬂuorescence-activated cell sorter–collected wild-type
(WT) and Sclpfn1 Lin2Sca-11Kit1Flk22CD342 cells were suspended in
300 mL of Hanks balanced salt solution/0.1% bovine serum albumin in
the upper chamber and allowed to migrate across the 5-mm pore inserts
(Corning-Costar) toward the lower chamber containingHanks balanced salt
solution/0.1% bovine serum albumin and 160 ng/mLCXCL12 (Peprotech).
Transmigrated cells were harvested after 4 hours. The transmigrated cells
and the cells that remained in the upper chamber were analyzed by ﬂow
cytometery.
Statistical analyses
Data are expressedasmean6 standarderrorof themean.Datawere analyzedby
the Student t-test and were considered statistically signiﬁcant if P, .05.
Results
Maintenance of BM HSCs requires Pfn1 function
To obtain an inducible loss-of-function model for pfn1 in HSCs, we
crossed pfn1ﬂ/ﬂmice3 with transgenic mice expressing the tamoxifen-
inducible Cre recombinase under the control of the Scl HSC enhancer,
which deletes ﬂoxed genes in HSCs and hematopoietic progenitors on
tamoxifen treatment10 (supplemental Table 1). The resultant Scl-Cre-
ER/pfn1ﬂ/ﬂ mice (Sclpfn1; Figure 1A) and the control mice (Scl-Cre-
ER/ pfn11/1) were injected with tamoxifen to induce Cre expression
in HSCs. Speciﬁc primers are designed to distinguish theWT, pfn1ﬂ/ﬂ,
Figure 1. Conditional deletion of pfn1 in HSCs. (A) Schematic of pfn1 floxed allele
showing deletion of floxed exon 1 following Cre recombinase activity. Use of Scl-Cre-
ERT results in specific deletion of the pfn1 gene in HSCs following tamoxifen treat-
ment. (B) Genotype analyses of LT-HSCs (Lin2Sca-11Kit1Flk22CD342, LSKFC) and
Lin1, Lin2, Lin2Kit1 (LK) cells and whole BM (WBM) cells at 1 and 6 days after
tamoxifen injections. Deletion of pfn1 is indicated by the arrow (700 bp).
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and pfn12/2mice (on tamoxifen treatment; supplemental Figure 1A).
Genotyping of BM LT-HSCs as Lin2Sca-11Kit1CD342Flk22
(LSKFC) cells and differentiated hematopoietic Lin1 cells of the
Sclpfn1 mice revealed that loss of pfn1 had occurred in HSCs, but not
in Lin1 cells at 24 hours after treatment of tamoxifen (Figure 1B).
This pfn1 loss was dramatically increased in all hematopoietic cells at
day 6 after the differentiation of HSCs (Figure 1B).
To evaluate the role of pfn1 inHSCmaintenance and function,we
analyzed the frequency and number of LSK cells and LSKFC cells
(as LT-HSCs) in control and Sclpfn1 mice at different time points
after tamoxifen treatment (Figure 2A-B). LSKFC cells in control
mice were 0.011 6 0.0038% and 0.012 6 0.0036% of the total
BM cells at days 8 and 14, respectively. In contrast, LSKFC cells
accounted for only 0.0058 6 0.0017% of BM cells at day 8 and
0.0008 6 0.00021% at day 14 in Sclpfn1 mice (Figure 2B). Total
numbers of BM cells in Sclpfn1 mice dramatically decreased from
day 8 to day 14, consistent with exhaustion of HSCs (supplemental
Figure 1B). Consistently, the total HSC number in BM decreased
from 5.36 0.0673 103 at day 0 to 0.0676 0.0193 103 at day 14
(Figure 2C). Meanwhile, lineage distribution in BM was changed at
day 14 in Sclpfn1 mice compared with the WT distribution with
increases in percentages of CD31 and B2201 lymphoid cells
and CD711Ter1191 erythroid cells, but decreases in Mac-11 and
Gr-11 myeloid cells (supplemental Figure 1C). A colony assay was
Figure 2. The maintenance of BM HSCs requires pfn1 function. (A) Representative flow cytometry profile of Lin2Sca-11Kit1 cells from control and Sclpfn1 mice. (B)
The frequency of LSKFC in the Sclpfn1 mouse was dramatically decreased compared with the control mouse (1.4% vs 0.01%) at day 14 after tamoxifen treatment.
Deletion of pfn1 over time is indicated by the arrow. (B-C) Quantification of HSC (Lin2Sca-11Kit1Flk22CD342) frequency and number in BM of control and Sclpfn1
mice (n 5 5-8) at different time points (*P , .05). (D) Competitive reconstitution analysis of control and Sclpfn1 HSCs treated with tamoxifen for 4 days. BM CD45.2 cells
(2 3 105 cells) from donor mice along with 2 3 105 freshly isolated CD45.1 competitor cells were transplanted into lethally irradiated CD45.1 recipient mice. The mice
(n 5 5 per group) were analyzed for engraftment through 16 weeks after transplant (*P , .05). (E) Multilineage contribution of donor cells in the recipients at 14 weeks
after transplant (n 5 5). (F) Control and Sclpfn1 donor cells (23 105 cells) along with 23 105 competitor cells were transplanted into lethally irradiated CD45.1 recipient mice.
These primary transplanted mice (n 5 5) were treated with tamoxifen at 8 weeks after transplant and were then analyzed for the engraftment from 2 to 17 weeks after
tamoxifen treatment. (*P , .05). Deletion of pfn1 at 2 weeks after tamoxifen treatment is indicated by the arrow. (G) Multilineage contribution of donor cells in the recipients
at 16 weeks after transplant (n 5 5).
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performed to assess the dynamics of progenitor cells after pfn1
deletion. As shown in supplemental Figure 1D-E, numbers of
myeloid progenitor cells, but not erythroid progenitors or B cell
progenitors, were dramatically decreased to 40.70 6 8.01% of the
control at 4 days after tamoxifen treatment. The ﬂow cytometry
analyses also showed that the common myeloid progenitors
decreased dramatically by .60% than the control (supplemental
Figure 1H-I). The loss of cellularity of BM and dislocation of
HSCs in bone marrow niches in pfn1-null mice were also evident
(supplemental Figure 1F-G). Overall, our data in Figure 2 and
supplemental Figure 1 indicate that pfn1 deletion results in the
exhaustion of HSCs and the fast cyclingmyeloid progenitors in the
mouse BM.
To further determine whether the reduction in phenotypic HSCs in
Sclpfn1 mice reﬂected an intrinsic defect, we performed 2 types of
competitive transplantation experiments. In the ﬁrst experiment, we
transplanted 2 3 105 BM cells from either tamoxifen-treated Sclpfn1
mice or control animals with 23 105 CD45.1 competitors into lethally
irradiatedCD45.1 recipients. Signiﬁcant numbers of donor-derived cells
were observed in the peripheral blood of mice injected with control
HSCs (23.21 6 1.53%, 47.97 6 3.47%, and 57.28 6 4.61% re-
population at 3, 8, and 16 weeks, respectively); however, donor
Sclpfn1 cells only contributed to minor chimerism (4.156 0.52%,
8.04 6 7.04%, and 11.69 6 11.15% repopulation at 3, 8, and 16
weeks, respectively; Figure 2D). Nevertheless, Sclpfn1 donor cells
did repopulate the lymphoid and myeloid lineages (Figure 2E),
indicating differentiation was not impaired in pfn12/2 HSCs.
Sclpfn1 donor cells treated with tamoxifen repopulated lethally
irradiated CD45.1 recipients at barely detectable levels (supple-
mental Figure 2), which further conﬁrmed that pfn1 plays a crucial
role in maintenance of HSC activity.
In the other experiment, we transplanted 2 3 105 Sclpfn1 cells
(without tamoxifen treatment) or control BM cells with 2 3 105
CD45.1 competitors into lethally irradiated CD45.1 recipients. Both
groups were repopulated at similar efﬁciencies (42.616 2.74% and
35.77 6 5.64%, respectively; Figure 2F) at 8 weeks after trans-
plantation.When pfn1 deletion was induced by tamoxifen treatment,
levels of the pfn1-deﬁcient HSCs signiﬁcantly decreased over time
from 35.776 5.64% at 4 weeks to 4.21 6 0.60% at 17 weeks after
treatment began (Figure 2F). The repopulation of the control group
remained relatively constant (46.54 6 5.78%, 50.71 6 6.36%,
54.03 6 8.07%, and 53.21 6 9.88% at weeks 4, 7, 10, and 17,
respectively). The pfn12/2 donor cells repopulated all lymphoid and
myeloid lineages (Figure 2G). Collectively, these results indicate
that pfn1 is essential for the repopulating activity of HSCs.
Spontaneous and constitutive mobilization of HSCs in
Sclpfn1 mice
A number of possible mechanisms may account for the decreased
HSC frequency and activity observed in Sclpfn1 mice including (1)
decreased proliferation of HSCs, (2) increased mobilization, and (3)
increased apoptosis. We ﬁrst determined the impact of pfn1
deﬁciency on HSC quiescence/proliferation by analyzing the cell
cycle proﬁle of pfn12/2 BM HSCs. Hoechst 33342 and pyronin Y
staining16 of sorted HSCs (as LSKFC cells) revealed no signiﬁcant
difference between Sclpfn1 and control mice at day 4 after tamoxifen
treatment. However, there was an ;50% decrease in G0 phase of
pfn12/2 HSCs compared with WT controls at day 8 after tamoxifen
treatment (Figure 3A). This decreased quiescence of pfn12/2 HSCs
in BM was further conﬁrmed by BrdU incorporation assays, which
showed twofold greater (24.3 6 4.2% vs 11.8 6 3.8% in HSCs and
36.76 4.3% vs 24.26 3.6% in LSK cells) incorporation of BrdU
into pfn12/2 HSCs or LSK cells compared with control HSCs or
LSK cells (Figure 3B). Therefore pfn12/2HSCs exhibited decreased
quiescence in BM.
Next, we testedwhether pfn1 plays a role in retainingHSCs in the
BM. To this end, we analyzed LT-HSC frequency and number in the
peripheral blood of Sclpfn1 and control mice. Beginning at day 4
after tamoxifen treatment, the frequency of circulating HSCs in
Sclpfn1 mice increased about threefold compared with controls
(Figure 3C). At days 8 and 14 after treatment with tamoxifen, the
frequencies of circulating Sclpfn1HSCswere dramatically increased
by up to 10-fold in Sclpfn1 mice relative to controls. Because the
spontaneous mobilization of LT-HSCs started at day 4 after tamoxifen
treatment (Figure 3C), concordantly with the decrease of the frequency
of HSCs in BM (starting after day 4; Figure 2B), HSC mobilization is
likely a cause of the decrease of HSCs in BM in Sclpfn1 mice.
To investigate themechanistic role of pfn1 in retention ofHSCs in
the BM, we performed a transwell experiment with control and
Sclpfn1HSCs treated for 8dayswith tamoxifen.As shown inFigure 3D,
Sclpfn1 HSCs had signiﬁcantly decreased chemoattraction for SDF-1
compared with control cells, indicating that pfn1 regulates the BM
retention of HSCs, possibly through SDF-1–mediated chemotaxis.
Both mobilization and homing are measures of HSC motility.
Although Sclpfn1 HSCs had drastically increased mobilization and
pfn1 deletion up-regulates CXCR4 expression in LT-HSCs (sup-
plemental Figure 1H,J), the Sclpfn1 HSCs did not show signiﬁcant
difference in homing to BM compared with controls (Figure 3E).
This result suggests that pfn1 is essential for the retention but not for
the immediate homing of HSCs in the BM niche. Therefore, pfn1
deﬁciency induces an uncommon uncoupling of homing and mobi-
lization of HSCs in BM.
It was reported that EGR1 regulates HSC migration and retention
in the BM niche, and their knockout showed similar phenotypes as
pfn12/2 mice.17,18 To test the possible role of pfn1 in regulation of
EGR1, we examined EGR1 expression in control and Sclpfn1 HSCs
treated with tamoxifen for 3 days using quantitative RT-PCR. In-
terestingly, we found that the EGR1 level in Sclpfn1 HSCs decreased
to 38.99 6 4.76% of that in controls (supplemental Figure 3A).
Another protein, MLL, which was shown to support HSC BM
retention,18 was also decreased in Sclpfn1 HSCs (supplemental
Figure 3B). To determine how pfn1 regulates HSC BM retention,
we demonstrated that Pfn1 was capable of interacting with a guanine
nucleotide-binding proteinGa13 (Figure 3F; supplemental Figure 3C),
which was known to transactivate the expression of EGR1.19
Importantly, a retroviral expression of EGR1 rescued the defective
retention of Sclpfn1 HSCs in the BM but not in the spleen and the
decreased quiescence of Sclpfn1 HSCs (Figure 3G-H). These results
indicate that Pfn1 interacts with Ga13, which up-regulates EGR1 to
maintain HSCs in the BM.
Finally, to determine the role of pfn1 in apoptosis of HSCs, we
assessed Annexin V and 7-aminoactinomycin D (7-AAD) staining of
LSKFC cells as a function of time after pfn1 deletion. As shown in
Figure 3I, apoptosis of HSCs was dramatically increased in Sclpfn1
mice compared with controls at 16 days but not at 4 days after
tamoxifen treatment. Furthermore, the increased apoptosis of Sclpfn1
HSCs can also be rescued by EGR1 (Figure 3J). Overall, Pfn1 plays
a signiﬁcant role in the survival of HSCs.
To understand the relationship between apoptosis and BM ex-
haustion of Sclpfn1 HSCs, we analyzed the growth of pfn12/2 and
control HSCs in vitro. Similar to the observed loss of quiescence
in vivo, null HSCs had faster cycling in culture than WT HSCs
(Figure 4A). This suggests that pfn1 negatively regulates HSC
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proliferation. The null HSCs expanded much more slowly than
their WT counterparts in vitro (Figure 4B-C). To explain these
seemingly contradictory observations, we analyzed apoptosis and
differentiation of control and pfn12/2HSCs in culture (Figure 4D;
supplemental Figure 4A). We found that null HSCs had signiﬁcantly
increased levels of apoptosis relative to controls (Figure 4D). Similar
to results obtained in vivo, pfn12/2 HSCs differentiated normally in
culture (supplemental Figure 4A). Overall, these in vivo and in vitro
results suggest that pfn1 supports the survival and quiescence of
HSCs. The deletion of pfn1 in HSCs led to increased apoptosis,
cycling, and mobilization of HSCs, all of which account for the
BM failure of the mutant mice.
Pfn1 supports glycolysis of HSCs
Previous studies suggested that some cytoskeleton molecules,
including moesin, g-actin, and coﬁlin-1, may be involved in
metabolic regulation.20 We recently demonstrated that HSCs have
a distinct metabolic proﬁle and prefer to use glycolysis rather than
mitochondrial oxidation as their main energy source.1We thus sought
to test whether pfn1, as an important cytoskeletonmolecule, plays a role
in HSC metabolism. To this end, we ﬁrst examined whether metabolic
properties of HSCs changed over the course of the cell cycle. We
collected LT-HSCs at G0 and G1 by ﬂuorescence-activated cell sorter
and measured their ATP content, oxygen consumption, and glycolytic
ﬂux relative to ATP level. We found that the G0 HSCs, which are
quiescent, had 41.1064.30%ATPcontent and3.5960.16-fold higher
glycolytic ﬂux per ATP than did the G1 population (Figure 5A). G0
HSCs also showed a lower level of oxygen consumption on average
(Figure 5A). These results, for the ﬁrst time, demonstrate that HSCs in
different stages of the cell cycle have different metabolic preferences.
Because pfn1 deletion in HSCs leads to decrease of G0 that
possesses greater glycotic ﬂux, we sought to test whether pfn1 plays
Figure 3. Spontaneous and constitutive mobilization of HSCs in Sclpfn1 mice. (A) Sclpfn1 BM HSCs are less quiescent than control HSCs. (Left) LT-HSCs (as Lin2
Sca-11Kit1Flk22CD342 cells) from a WT mouse, stained with Hoechst 33342 and pyronin Y, were analyzed for cell cycle stage. (Right) The percentages of G0 cells in control and
Sclpfn1 mice (n 5 3-4) at days 4 and 8 after tamoxifen treatment are shown (*P , .05). (B) BrdU incorporation indicates a decreased cycling in HSCs isolated from control mice
compared with Sclpfn1 mice (n 5 3; *P , .05). (C) Relative frequency of LT-HSCs in peripheral blood (PB) was analyzed over time in control and Sclpfn1 mice after tamoxifen
treatment (n5 3-7; *P, .05). (D) The migrations of LT-HSCs (as Lin2Sca-11Kit1Flk22CD342 cells) isolated from control and Sclpfn1 mice 8 days after tamoxifen treatment were
compared in a transwell experiment (n 5 3; *P , .05). (E) Control and Sclpfn1 HSCs home equivalently to recipient BM. BM from control or Sclpfn1 mice (n 5 5) was labeled
with 5- and 6-carboxyfluorescein succinimidyl ester (CFSE), and 1 3 107 cells were transplanted into lethally irradiated recipients. After 16 hours, the total percentage of
CFSE1 cells in the BM, spleen, and liver and LT-HSCs (CFSE1Lin2Sca-11Kit1 Flk22CD342 cells) in BM were determined by flow cytometry. (F) Lysates of WT mouse BM
cells were coimmunoprecipitated with anti-Ga13 antibody or control rabbit IgG, and precipitation was then determined by western blotting using anti-Ga13 and anti-pfn1
antibodies (G-H) Rescue of Sclpfn1 LT-HSCs by EGR1. Control or EGR1 overexpressed Sclpfn1 BM cells were transplanted into CD45.1 recipients with competitors. Mice
were treated with tamoxifen after 5 weeks. (G) Percentages of donor-derived CD45.21 LT-HSCs were determined in BM and spleen (n 5 3-4, *P , .05). (H) LT-HSCs
were sorted from the BM of control or EGR1 rescued mice, and cell cycle was then measured by Hoechst 33342 and pyronin Y staining (n 5 3-4, *P , .05). (I) Control and
Sclpfn1 Lin2Sca-11Kit1Flk22CD342 cells were analyzed for apoptosis by using Annexin V/7-AAD staining (n 5 3-5; *P , .05). (J) LT-HSCs from the BM of control or EGR1
rescued mice were cultured for 8 days, and apoptosis was measured (n 5 3-4; *P , .05).
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a role in regulation of HSC metabolism. We started to measure the
expression of hypoxia inducible factor 1 (Hif-1)a, an important
regulator of hypoxia and metabolism,1,21 by real-time RT-PCR in
control and pfn12/2 HSCs. As shown in Figure 5B, Hif-1a
expression was dramatically decreased to 35.91 6 2.40% or
27.026 0.09% at day 1 or 3, respectively, after tamoxifen treatment
in null HSCs. This result is in agreement with our ﬁnding that pfn1
up-regulates EGR1 (supplemental Figure 3A; Figure 6E) and the
fact that EGR1 directly transactivates Hif-1a 22 (Figure 6D,F). Our
results thus suggest that pfn1 may play a role in regulation of
glycolysis and mitochondrial oxidation. Indeed, the HSC-speciﬁc
deletion of pfn1 resulted in decreased glycolytic ﬂux per ATP
(40.56 0.94% compared with that of controls) at only 2 days after
tamoxifen treatment (Figure 5C). At 8 days after tamoxifen
treatment, the Sclpfn1 HSCs had 6.56 6 1.42-fold increased
levels of ATP, a 2.5-fold (2.50 6 0.12%) increase of oxygen
consumption, and a 97.05 6 0.21% decrease of glycolytic ﬂux
per ATP compared with controls (Figure 5D). Consistently, the
glycolysis-related enzymes were down-regulated and Kreb cycle–
related enzymes PDHA1 and PDHB were up-regulated in Sclpfn1
HSCs (supplemental Figure 5A-B). Interestingly, this metabolic
switch on pfn1 deletion is speciﬁc to HSCs, because it did not occur
in various hematopoietic progenitors (supplemental Figure 5C-E).
These results clearly demonstrate that deletion of pfn1 results in
a switch from anaerobic glycolytic metabolism to oxidative phos-
phorylation in HSCs.
To identify the possible cause for this metabolic switch in HSCs
on pfn1 deletion, we examined the ATP production and oxygen
consumption of control and Sclpfn1 HSCs during in vitro culture
(supplemental Figure 4B-C). Although the in vitro cultured Sclpfn1
HSCs have increased apoptosis (Figure 4D), unlike the in vivo
situation, they did not show a metabolic switch (supplemental
Figure 4B-C). In addition, the in vivo metabolic switch happens in
pfn1-deleted HSCs much earlier than the apoptosis changes. These
results indicate that the altered metabolic proﬁling of Sclpfn1 HSCs
does not result from the apoptosis of Sclpfn1 HSCs. Given that pfn1
up-regulates EGR1 (supplemental Figure 3A) that suppresses
mobilization17 and EGR1 transactivates Hif-1a22 (Figure 6D-F) and
partially rescues pfn1-null metabolic phenotype (supplemental
Figure 3D), we reasoned that the change of metabolic proﬁling on
pfn1 deletion intrinsically links to the mobilization of HSCs.
Mitochondria are considered themajor source ofROS in cells and
play important roles in aging, degenerative diseases, and HSC
dysfunction.23-25 We found that the level of mitochondrial super-
oxide (MitoSOX) is much lower in G0 cells than G1 cells in wild-
type LT-HSCs, and MitoSOX levels in either G0 or G1 cells of
Sclpfn1 LT-HSCs are higher than that of controls, respectively
(Figure 5E). Accordingly, the mitochondrial potential in these cells
showed a similar trend (supplemental Figure 5F). Our results are
consistent with the view that ROS can induce loss of quiescence and
apoptosis of HSCs.26 Our previous results indicate that ROS pro-
duction in HSCs plays an important role in regulation of the
metabolic phenotype and cell fates.15 To investigate whether ROS is
responsible for the phenotypes of Sclpfn1 HSCs, we treated Sclpfn1
and control mice with the antioxidant NAC for 7 to 8 days and then
examined the cell fates of HSCs. As shown in Figure 5F, the level of
ROS in Sclpfn1 HSCs was signiﬁcantly higher than in control cells
and was statistically decreased after an 8-day treatment with NAC.
Interestingly, NAC treatment reversed the loss of quiescence of the
null HSCs (Figure 5G; supplemental Figure 5G) but had no effect on
HSC frequency or apoptosis in Sclpfn1 mice (Figure 5H-I; supple-
mental Figure 5H-I). Taken together, these data indicate that
metabolic changes are one of the earliest events in pfn1-deﬁcient
HSCs in BM, which accounts for their loss of quiescence.
Actin and poly-proline binding are critical to pfn1’s function
in HSCs
Previous studies showed that the actin binding and the poly-proline
binding ability of pfn1 are critical for the ﬁssion yeast viability
and chondrocyte function.3,27 To investigate the relative contribu-
tions of actin and nonactin ligands to pfn1 activity in HSCs, we
infected Sclpfn1 HSCs with retroviruses encoding WT pfn1, an
actin binding–deﬁcient point mutant of pfn1 (R74E), or pfn1 point
mutants (Y6D and H133S) with reduced afﬁnities for poly-proline.3
Five weeks after transplantation of the infected HSCs, tamoxifen was
Figure 4. Pfn1 supports the survival of HSCs. (A)
Cultured HSCs were stained with Hoechst 33342 and
pyronin Y and analyzed for cell cycle stage. The
percentages of G0 cells in cultured control and Sclpfn1
HSCs are shown (n 5 3; *P , .05). (B) LT-HSCs (as
Lin2Sca-11Kit1Flk22CD342 cells) were isolated from
control and Sclpfn1 mice 4 days after tamoxifen
treatment and cultured in STF medium for 8 to 10
days. Figures are representative for samples after
a 10-day culture. (C) Quantification of control and
Sclpfn1 HSCs after 10 days in culture (n5 3; *P, .05).
(D) Cultured HSCs from control and Sclpfn1 mice
were analyzed for apoptosis using Annexin V/7-AAD
staining (n 5 3; *P , .05).
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Figure 5. Pfn1 regulates metabolism of HSCs. (A) Measurement of ATP content, oxygen consumption, and labeled glycolytic flux per ATP in G0 and G1 fractions of
LT-HSCs (as Lin2Sca-11Kit1Flk22CD342 cells) (n5 3-6; *P, .05). (B) Hif-1a expression in control and Sclpfn1 HSCs at days 1 and 3 after tamoxifen treatment (n5 3; *P, .05).
(C-D) Metabolic profiles (ATP content, oxygen consumption, and glycolytic flux per ATP) in control and Sclpfn1 HSCs at (C) day 2 or (D) day 8 after tamoxifen treatment. Sclpfn1
HSCs are much less glycolytic (n 5 3-6; *P , .05). (E) Mitochondrial super-oxide (MitoSOX) was analyzed in G0 and G1 cells from control and Sclpfn1 LT-HSCs (n 5 3).
(F-I) Control and Sclpfn1 mice were treated with tamoxifen for 7 days followed by NAC treatment of another 8 days. (F) Levels of ROS were determined by analysis for
carboxy-DCFDA, and percentage of DCFDA1 LT-HSCs are shown (n 5 4-6; */**/***P , .05). (J) Cell cycle status, (H) frequency, and (I) levels of apoptosis of HSCs were
analyzed (n 5 3; *P , .05).
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used to induce deletion of pfn1 to produce pfn12/2 donor HSCs. As
expected, retroviral infection with the WT pfn1, but not the actin
binding–deﬁcient mutant or the poly-proline binding–deﬁcient mu-
tants, was able to rescue the repopulation activity of null HSCs
(Figure 6A-C). Retroviral expression of EGR1 was able to increase
Hif-1a level in Sclpfn1 cells (Figure 6D,F), and WT pfn1 expres-
sion also up-regulated EGR1 and Hif-1a expression (Figure 6E-F).
By contrast, the actin binding–deﬁcient mutant and the poly-
proline binding–deﬁcient mutant pfn1 had a lower ability to elevate
EGR1 and Hif-1a expression (Figure 6E-F). It is of note that the
proline-binding mutants skewed myeloid/B-lymphoid lineage repo-
pulation (Figure 6C). Taken together, these data suggest that the actin
binding and poly-proline binding activities of pfn1 are important for
its regulation of HSC activity.
In summary,weprovide strongevidence that pfn1plays critical roles
in the maintenance of multiple cell fates and metabolism of HSCs. As
Figure 6. Actin and poly-proline binding is critical to pfn1’s function in HSCs. (A-B) E16 fetal liver Sclpfn1 Lin2 cells were infected with retrovirus encoding WT, actin
binding–deficient pfn1, or poly-proline-binding–deficient pfn1 and were then transplanted into lethally irradiated CD45.1 recipients. Five to 10 weeks later, the mice were
treated with tamoxifen for 2 weeks. Donor engraftment at indicated time after transplant is shown (n 5 5). (C) Multilineage contribution of donor cells in recipients at 10 or 15
weeks after transplant (n5 5). (D) Control or EGR1 retrovirally expressed Sclpfn1 BM cells were transplanted into CD45.1 recipients with competitors. Mice were treated with
tamoxifen after 5 weeks. Donor-derived CD45.21 LSK cells were sorted, and expression of Hif-1a was measured (n5 3). (E) Pfn1 or Pfn1 mutants were retrovially expressed
in WT LSK cells, and expression of EGR1 was measured (n 5 3). (F) Pfn1, Pfn1 mutants, or EGR1 was retrovially expressed in WT LSK cells, and expression of Hif-1a was
measured (n 5 3). *P , .05, different from control values; **P , .05, different from mutant pfn1 values.
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summarized in supplemental Figure 6, the loss of pfn1 in HSCs leads
to increased mobilization and the metabolism switch, and apoptosis
of HSCs over time in vivo, all of which contribute to BM failure.
Discussion
It is well established that pfn1 plays critical roles in cell survival,
proliferation, and motility in various cell types.2-5,8,27 Its in vivo role
in stem cells, however, has not been studied. Here we showed that
Pfn1 plays multiple essential roles in HSCs and is required for steady-
state hematopoiesis. Different from its migration/proliferation roles in
many cell types,3,5-7 pfn1 is key to maintaining the retention and
quiescence of HSCs in the BM. It is also critical for the survival but
plays no signiﬁcant role in differentiation or homing of HSCs.
Therefore, although pfn1 is ubiquitously expressed, it has speciﬁc
function in HSCs. This function is partially contributed by its up-
regulation of the expression of EGR1, which has been shown to be
required for the quiescence and retention of HSCs in the BM.17,18
Although it is known that the forced expression of EGR1 causes
changes in differentiation,28 we demonstrated that it can partially
rescue the Sclpfn1 HSC phenotype. Importantly, EGR1 is known to
be able to bind to and activate the promoter of Hif-1a,22 as conﬁrmed
in our system. Therefore, at least partially through the axis of pfn1/
Ga13/EGR1, pfn1 regulates BM retention of HSCs that contributes to
maintaining their glycolytic metabolism. Treatment of pfn1-deﬁcient
micewithNAC reversed the ROS level and loss of quiescence ofHSCs,
suggesting that pfn1-maintained metabolism is required for the
quiescence of HSCs. We further demonstrated that pfn1’s function in
HSCs depends on its actin-binding and poly-proline–binding activities.
Recently, we demonstrated that HSCs have a distinct metabolic
proﬁle, and Meis1 and Hif-1a are involved in the regulation of this
unique metabolism.1,15 However, the relationship between metabo-
lism and cell fates (quiescence, self-renewal, differentiation, apopto-
sis, and motility) of HSCs is not known. Here, our results suggest that
a metabolic quiescence is mechanistically linked to the cell cycle
quiescence of stem cells.We showed that pfn1 plays an important role
in regulation of the metabolism of HSCs. Deletion of pfn1 in HSCs
leads to down-regulation of the metabolism master regulator Hif-1a
and a switch from glycolysis to mitochondrial respiration. Impor-
tantly, this metabolic change happened earlier than the loss of
quiescence of HSCs. It is well known that mitochondrial oxidation is
accompanied by signiﬁcantly increased ROS production,29-33 and the
free radical scavenger NAC restored quiescence of pfn1-null HSCs.
Therefore the metabolic preference of HSCs regulates HSC cell cycle
status. We also found that quiescent HSCs (at G0) have higher levels
of glycolysis than proliferating HSCs (at G1). Therefore, the
altered metabolic proﬁling of the pfn1-null HSCs may also
partially contribute to the cell cycle change. We speculate that
a feedback loop controls the metabolism and cell cycle state of
stem cells. Further investigation will be needed to uncover the
underlying mechanism for this regulation.
The relationships among different cell fates of HSCs are com-
plicated. For example, whether homing and mobilization are 2 sides
of the same coin is not clear, although in many cases homing and
mobilization are clearly coupled. Expression of integrin a4/b1 and
SDF1/CXCR4 are needed for both homing enhancement and retention
of HSCs in BM.34,35 However, Gas is critical for the homing but not
the mobilization of HSCs.36 That there are meaningful molecular
distinctions between homing, engraftment, and retention processes
is also demonstrated by our ﬁnding that pfn1 deﬁciency uncouples
these events. Unlike Gas, pfn1 is essential for the mobilization but
not homing of HSCs. Our results also suggest that quiescence and
mobilization/survival of HSCs can be independent events. More
detailed studies, including those using high-resolution, real-time
imaging tools to elucidate the roles of pfn1 in regulation of the
activities of HSCs in and outside of BM, will provide important new
insights into the relationships among HSCs, niche, and metabolism.
Here we demonstrated that both the actin-binding and the poly-
proline–binding abilities of pfn1 are essential to HSC activity. In
future studies, it will be important to dissect which of these 2
activities of pfn1 is responsible for BM retention, survival, dif-
ferentiation, and metabolic preference of HSCs. The role of the
proline-binding function will be particularly interesting. It is
known that proﬁlins interact with .12 proline-rich peptide-
containing proteins, including those involved in cytoskeleton
polymerization (Arp2/3), focal adhesion (Ena-vasodilator stimulated
phosphoprotein, Palladin, Mena, and vasodilator-stimulated phos-
phoprotein), synaptic scaffold synthesis (Delphilin, Aczonlin, Drebrin
and Gephyrin), membrane trafﬁcking (valosin containing protein,
Clathrin, and Annexin I), r GTPase signaling (WAS/WASL inter-
acting protein, WAS protein family, member 1, Wiskott-Aldrich
syndrome, formin-related gene in leukocytes and mDiaphanous), and
nuclear export (Exportin 6 and survival of motor neuron 1).37,38 Here
we added 1moremolecule, Ga13, to this list, and our study suggested
that EGR1, as a target of Ga13, is a mediator of pfn1’s function in
HSC BM retention and links pfn1 to Hif-1a up-regulation and
glycolytic metabolism. It is noteworthy that the Pfn-null HSC
phenotype is much more severe than that of the EGR1-null mice.
Given the large number of pfn1-interacting proteins, it is likely
that the pfn1/Ga13/EGR1 axis represents a branch of the pfn1
downstream effector network. The clariﬁcation of the contribution of
these and other molecules to pfn1 function in HSCs will lead to
a signiﬁcantly improved understanding of the interplay between stem
cells and their niches and the pathology of HSC-related diseases.
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